Keppra
Product Images NDC 16590-134

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 16590-134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image 500mg (Keppra 500mg 134)

KEPPRA 500 mg tablets packaging label from STAT RX USA LLC. The label states 30 tablets per package, containing the active ingredient Levetiracetam 500 mg. It includes NDC 16590-134-30, manufacturing and lot information, storage instructions, and a warning that the drug may cause drowsiness or dizziness. The label also specifies the product is prescription-only and includes a caution to keep out of reach of children.*

FDA Label Image

Label Image 750mg (Keppra 750mg 135)

KEPPRA 750 mg tablet label, packaging 30 tablets, distributed by STAT RX USA in Gainesville, GA. The label states it is a generic for Levetiracetam 750 mg tablets, manufactured by UCB Pharma, Inc., Smyrna, GA. The NDC number 16590-135-30 is visible. The label includes warnings about possible drowsiness or dizziness and instructions to keep out of reach of children.*

FDA Label Image

Chemical Structure (Keppra 01)

Chemical structure of the active ingredient in KEPPRA. The diagram shows a pyrrolidone ring with attached amide and alkyl groups, representing the molecular configuration.*

FDA Label Image

Figure (Keppra 02)

A vertical bar graph comparing the percentage of patients among three groups: Placebo (95 patients), KEPPRA 1000 mg/day (97 patients), and KEPPRA 3000 mg/day (101 patients). The y-axis shows the percentage of patients, with KEPPRA 1000 mg/day and 3000 mg/day groups having notably higher percentages than placebo.*

FDA Label Image

Figure (Keppra 03)

A bar chart comparing the percentage of patients across three groups: Placebo (N=111) at 6.3%, KEPPRA 1000 mg/day (N=106) at 20.8%, and KEPPRA 2000 mg/day (N=105) at 35.2%. The y-axis shows the percentage of patients, ranging from 0% to 45%, and each bar is labeled with its corresponding percentage.*

FDA Label Image

Figure (Keppra 04)

A bar chart comparing the percentage of patients with an outcome between two groups: Placebo (N=104) at 14.4% and KEPPRA 3000 mg/day (N=180) at 39.4%. The y-axis shows percent of patients from 0% to 45%.*

FDA Label Image

Figure (Keppra 05)

A bar chart comparing the percentage of patients for Placebo and KEPPRA groups. The Placebo group (N=97) shows 19.6% of patients, while the KEPPRA group (N=101) shows 44.6%. The y-axis is labeled '% of patients' and ranges from 0% to 45%. This chart illustrates a comparison of patient percentages between the two groups.*

FDA Label Image

Figure (Keppra 06)

A bar chart comparing the percentage of patients between Placebo and KEPPRA groups. The Placebo group (N=84) shows 45.2% of patients, while the KEPPRA group (N=79) shows 72.2%. The y-axis represents the percentage of patients from 0% to 100%, and the x-axis labels the two groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.